Answers are grounded in this paper and cite their sources.
Opioid-free anaesthesia (OFA) is increasingly used to limit intraoperative opioids in oncological surgery, but evidence in radical prostatectomy is scarce. We compared OFA with a remifentanil-based technique in laparoscopic radical prostatectomy (LRP) on a uniform multimodal and regional analgesic background. Adult men undergoing LRP were randomized to OFA (dexmedetomidine plus ketamine, no intraoperative opioids) or a remifentanil-based technique. Both groups received identical multimodal premedication, bilateral quadratus lumborum block, sevoflurane maintenance and identical oxycodone patient-controlled analgesia (PCA). The primary outcome was total oxycodone consumption over the first 24 postoperative hours. Pre-specified secondary outcomes included Numeric Rating Scale (NRS) pain scores, postoperative nausea and vomiting (PONV), serum creatinine change to day 1, and the demanded-to-delivered PCA bolus ratio. Fifty-seven patients were analysed (OFA n = 32; remifentanil n = 25). Total 24-h oxycodone consumption did not differ (location-shift estimate − 2.0 mg, 95% CI -8.0 to 6.0; p = 0.556), and neither NRS scores nor PONV differed significantly. The demanded-to-delivered PCA bolus ratio was lower with OFA (location-shift estimate − 0.20, 95% CI -0.267 to 0.000; p = 0.006), as was the early rise in serum creatinine (location-shift estimate − 7.7 µmol/L, 95% CI -13.9 to -1.1; p = 0.034). Intraoperative bradycardia and hypotension did not differ significantly. In LRP, no statistically significant difference in 24-hour oxycodone consumption or pain scores was detected between OFA and remifentanil-based anaesthesia. The trial was not designed or powered for equivalence or non-inferiority, and these findings therefore do not establish comparable efficacy. Differences in two pre-specified secondary outcomes (a lower demanded-to-delivered PCA ratio and a smaller early creatinine rise) are hypothesis-generating. Because recruitment was curtailed, findings require confirmation in adequately powered trials, ideally in robot-assisted prostatectomy. ClinicalTrials.gov NCT06380244, registered 23 April 2024.
No takes yet. Share an insight, caveat, or question.
Pawel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: